Stockscreener 앱 받기
3.30
1.54%
0.05
시장 영업 전:
3.31
0.01
+0.30%
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
Why NRx Pharmaceuticals Inc. Equity Warrant stock could outperform in 2025Quarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
NRx Pharmaceuticals (NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM) - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM) - The Globe and Mail
Quantitative breakdown of NRx Pharmaceuticals Inc. Equity Warrant recent moveTrade Ideas & Free Safe Entry Trade Signal Reports - newser.com
What Fibonacci levels say about NRx Pharmaceuticals Inc. reboundShort Setup & Daily Technical Forecast Reports - newser.com
Using flow based indicators on NRx Pharmaceuticals Inc.July 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Will NRx Pharmaceuticals Inc. stock gain from government policies2025 Key Lessons & High Accuracy Investment Signals - newser.com
NRx files ANDA for preservative-free ketamine amid US drug shortage - Investing.com Australia
Is NRx Pharmaceuticals Inc. stock safe for conservative investorsQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Is NRx Pharmaceuticals Inc. Equity Warrant forming a reversal pattern2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Does NRx Pharmaceuticals Inc. qualify in momentum factor screeningJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - newser.com
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - Great Falls Tribune
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion in 2034; - openPR.com
How to integrate NRx Pharmaceuticals Inc. into portfolio analysis tools2025 Analyst Calls & Growth Focused Entry Reports - newser.com
What Fibonacci levels say about NRx Pharmaceuticals Inc. Equity Warrant rebound2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
NRXP's Rating Maintained at 'Buy' by D. Boral Capital | NRXP Sto - GuruFocus
Can trapped investors hope for a rebound in NRx Pharmaceuticals Inc. Equity WarrantBond Market & Risk Controlled Swing Trade Alerts - newser.com
Visual trend scoring systems applied to NRx Pharmaceuticals Inc. Equity WarrantChart Signals & Community Trade Idea Sharing Platform - newser.com
Why NRx Pharmaceuticals Inc. Equity Warrant stock is seen as undervaluedQuarterly Investment Review & Daily Growth Stock Tips - newser.com
Nrx pharmaceuticals re-files anda for ketafree to fda - MarketScreener
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files - GlobeNewswire
$3.35B Market by 2034: NRx Develops Toxin-Free Ketamine as US Drug Shortage Continues - Stock Titan
Does NRx Pharmaceuticals Inc. show high probability of rebound2025 Retail Activity & Target Return Focused Stock Picks - newser.com
How to recover losses in NRx Pharmaceuticals Inc. stockJuly 2025 Setups & Expert Curated Trade Setups - newser.com
NRx Pharmaceuticals Inc Equity Warrant Stock Analysis and ForecastSupport and Resistance Levels & Small Budget Big Profits - earlytimes.in
Will NRx Pharmaceuticals Inc. Equity Warrant stock outperform international peers2025 Price Targets & Weekly Stock Breakout Alerts - newser.com
NRX Pharmaceuticals Gains FDA Approval for KETAFREE™ - MSN
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree - MSN
What to do if you’re stuck in NRx Pharmaceuticals Inc. Equity WarrantLayoff News & Verified Short-Term Plans - newser.com
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Joplin Globe
NRXP Stock Rating Maintained as 'Buy' by D. Boral Capital | NRXP - GuruFocus
NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital - MarketBeat
NRX Pharmaceuticals stock surges after FDA grants Suitability Petition By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product - Yahoo Finance
FDA Approval of Suitability Petition on Preservative-Free Ketamine Drug Supports $40 Analyst Target; $3 Billion Suicidal Depression Market: $NRXP - FinancialContent
NRx Pharmaceuticals Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine - citybiz
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product - The Globe and Mail
NRX Pharmaceuticals Gets FDA Approval of Suitability Petition for Preservative-Free Ketamine; Shares Rise - MarketScreener
Oklahoma City NewsThe Oklahoman - FinancialContent
NRX Pharmaceuticals stock surges after FDA grants Suitability Petition - Investing.com
Nrx Pharmaceuticals receives notification of US Food and Drug Administration approval of suitability petition - MarketScreener
NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - Investing News Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine - The Manila Times
NRx Pharmaceuticals Receives FDA Approval for Suitability Petition for KETAFREE™, Enabling Re-filing of ANDA for Preservative-Free Ketamine - Quiver Quantitative
Toxic-Free Ketamine Breakthrough: NRx Pharma Secures Critical FDA Approval for $750M Market Opportunity - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of "Buy" by Analysts - MarketBeat
2.36%
1.10%
자본화:
|
볼륨(24시간):